Hangzhou Yuancao Pharmaceutical

Hangzhou Yuancao Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, including non-alcoholic steatohepatitis (NASH/MASH) and type 2 diabetes, as well as oncology. Its lead candidate, YC-1102, is a highly selective thyroid hormone receptor beta (THR-beta) agonist designed to treat MASH with an optimized safety and efficacy profile. Yuancao leverages its internal R&D capabilities and a team of experienced pharmaceutical professionals to advance a pipeline of candidates targeting high-unmet-need chronic conditions. The company has successfully secured significant venture capital funding from prominent investors to support its clinical programs.